KR20180088690A - 골수종의 치료 또는 진행의 모니터링 - Google Patents

골수종의 치료 또는 진행의 모니터링 Download PDF

Info

Publication number
KR20180088690A
KR20180088690A KR1020187018220A KR20187018220A KR20180088690A KR 20180088690 A KR20180088690 A KR 20180088690A KR 1020187018220 A KR1020187018220 A KR 1020187018220A KR 20187018220 A KR20187018220 A KR 20187018220A KR 20180088690 A KR20180088690 A KR 20180088690A
Authority
KR
South Korea
Prior art keywords
nucleic acid
cell
kras
nras
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187018220A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 스펜서
스리두르가 미트라프라부
Original Assignee
알프레드 헬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905013A external-priority patent/AU2015905013A0/en
Application filed by 알프레드 헬스 filed Critical 알프레드 헬스
Publication of KR20180088690A publication Critical patent/KR20180088690A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187018220A 2015-12-03 2016-12-02 골수종의 치료 또는 진행의 모니터링 Withdrawn KR20180088690A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015905013A AU2015905013A0 (en) 2015-12-03 Monitoring treatment or progression of myeloma
AU2015905013 2015-12-03
AU2016903019A AU2016903019A0 (en) 2016-08-01 Monitoring treatment or progression of myeloma (2)
AU2016903019 2016-08-01
PCT/AU2016/051191 WO2017091865A1 (en) 2015-12-03 2016-12-02 Monitoring treatment or progression of myeloma

Publications (1)

Publication Number Publication Date
KR20180088690A true KR20180088690A (ko) 2018-08-06

Family

ID=58796005

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187018220A Withdrawn KR20180088690A (ko) 2015-12-03 2016-12-02 골수종의 치료 또는 진행의 모니터링

Country Status (8)

Country Link
US (1) US20180282820A1 (cg-RX-API-DMAC7.html)
EP (1) EP3384050A4 (cg-RX-API-DMAC7.html)
JP (2) JP2018537128A (cg-RX-API-DMAC7.html)
KR (1) KR20180088690A (cg-RX-API-DMAC7.html)
CN (1) CN108603232A (cg-RX-API-DMAC7.html)
AU (1) AU2016363113A1 (cg-RX-API-DMAC7.html)
CA (1) CA3007426A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017091865A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ, インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
EP4428863A3 (en) 2015-05-11 2024-12-11 Natera, Inc. Methods and compositions for determining ploidy
JP7280044B2 (ja) 2016-04-15 2023-05-23 ナテラ, インコーポレイテッド 肺癌の検出方法
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN110945136A (zh) 2017-06-20 2020-03-31 威斯康星州立大学医学院 使用总无细胞dna评估移植并发症风险
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
CN107881233A (zh) * 2017-10-31 2018-04-06 天津协和华美医学诊断技术有限公司 一种检测骨髓瘤相关基因群的检测试剂盒
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3737773B1 (en) 2018-01-12 2023-04-12 Natera, Inc. Novel primers and uses thereof
DK3781714T3 (da) 2018-04-14 2026-03-30 Natera Inc Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna
EP3784805A1 (en) * 2018-04-23 2021-03-03 Inivata Limited Method for predicting and monitoring response to an immune checkpoint inhibitor
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
JP7407193B2 (ja) 2018-08-08 2023-12-28 イニヴァータ リミテッド 可変の複製多重pcrを使用した配列決定方法
JP2022513399A (ja) * 2018-10-29 2022-02-07 モレキュラー ステソスコープ, インコーポレイテッド 無細胞メッセンジャーrnaを使用した骨髄の特徴付け
CN114072546A (zh) * 2018-10-30 2022-02-18 分子听诊器公司 无细胞rna文库制备
EP3899033A4 (en) * 2018-12-17 2022-10-19 The Medical College of Wisconsin, Inc. Assessing risk with total cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US20210087638A1 (en) * 2019-09-23 2021-03-25 Dana-Farber Cancer Institute, Inc. Next-generation sequencing assay for genomic characterization and minimal residual disease detection in the bone marrow, peripheral blood, and urine of multiple myeloma and smoldering myeloma patients
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
AU2020378435B2 (en) * 2019-11-06 2026-07-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
FR3105738B1 (fr) * 2019-12-26 2024-01-05 P M B Dispositif d’irradiation collaboratif
CN112698037B (zh) * 2021-03-25 2021-06-25 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
JP2024527504A (ja) * 2021-06-16 2024-07-25 オンコノヴァ セラピューティクス, インコーポレイテッド がんを処置するための方法および組成物
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2734179A1 (en) * 2008-08-12 2010-02-18 The Ohio State University Research Foundation Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EP2776586B1 (en) * 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US20160032396A1 (en) * 2013-03-15 2016-02-04 The Board Of Trustees Of The Leland Stanford Junior University Identification and Use of Circulating Nucleic Acid Tumor Markers
WO2015058176A1 (en) * 2013-10-19 2015-04-23 Trovagene, Inc. Detecting mutations in disease over time

Also Published As

Publication number Publication date
JP2018537128A (ja) 2018-12-20
CN108603232A (zh) 2018-09-28
AU2016363113A1 (en) 2018-06-07
WO2017091865A1 (en) 2017-06-08
US20180282820A1 (en) 2018-10-04
JP2022000059A (ja) 2022-01-04
EP3384050A1 (en) 2018-10-10
CA3007426A1 (en) 2017-06-08
EP3384050A4 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
JP2022000059A (ja) 骨髄腫の治療または進行のモニタリング
US20260055464A1 (en) Methods for profiling and quantitating cell-free rna
JP7334122B2 (ja) 妊娠高血圧腎症に特異的な循環rnaシグネチャー
CA3192386A1 (en) Metastasis predictor
EP2764122A2 (en) Methods and devices for assessing risk to a putative offspring of developing a condition
WO2015069954A1 (en) Targeted screening for mutations
KR101828125B1 (ko) 다발성 경화증에서의 진단 miRNA 프로파일
US20160068914A1 (en) Plasma cell disorders
EP3768864A1 (en) Immune repertoire monitoring
US20240084389A1 (en) Use of simultaneous marker detection for assessing difuse glioma and responsiveness to treatment
WO2025096476A1 (en) Use of multi-nucleotide and structural variants for improved sensitivity and specificity of circulating tumor dna assays
JP2026505350A (ja) 尿中の腎同種移植片拒絶反応遺伝子を同定するための方法およびそれらの測定を行うことの有用性
CN118139987A (zh) 用于cfrna和cftna靶向ngs测序的组合物和方法
JP2022504237A (ja) 処置に対する反応をモニタリングする方法
WO2014074609A2 (en) Methods and compositions for the diagnosis of multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211202

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20220302

WITB Written withdrawal of application